Alert: Rating Downgrade (8/9/24)-Astrazeneca PLC (NASDAQ: AZN).

out_logo_500#22730.jpg

Stock Rating Downgrade

The Value Trend Rating for Astrazeneca PLC (NASDAQ: AZN) fell significantly in recent days from A to C reflecting eroding fundamentals and low Appreciation Potential. Details supporting this lower rating are included in our next report.

out_mm#22730.jpg

Recent Price Action

Astrazeneca PLC (NASDAQ: AZN) stock declined slightly by -0.8% on 8/9/24. The stock closed at $81.19. However, trading volume in this decline was below average at 80% of normal. The stock has been exceptionally strong relative to the market over the last nine months but is unchanged during the last week.

Current PriceTarget Research Rating

AZN is expected to continue to be a major Value Builder reflecting capital returns that are forecasted to be above the cost of capital.

Astrazeneca has a current Value Trend Rating of C (High Neutral). This rating combines contradictory signals from two proprietary PTR measures of a stock’s attractiveness. Astrazeneca has a slightly negative Appreciation Score of 35 but a good Power Rating of 81, triggering the High Neutral Value Trend Rating.

Be the first to comment

Leave a Reply

Your email address will not be published.


*